JP2022531894A5 - - Google Patents

Info

Publication number
JP2022531894A5
JP2022531894A5 JP2021566144A JP2021566144A JP2022531894A5 JP 2022531894 A5 JP2022531894 A5 JP 2022531894A5 JP 2021566144 A JP2021566144 A JP 2021566144A JP 2021566144 A JP2021566144 A JP 2021566144A JP 2022531894 A5 JP2022531894 A5 JP 2022531894A5
Authority
JP
Japan
Prior art keywords
antibody
day
pharmaceutically acceptable
administered
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021566144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/063101 external-priority patent/WO2020225456A1/en
Publication of JP2022531894A publication Critical patent/JP2022531894A/ja
Publication of JP2022531894A5 publication Critical patent/JP2022531894A5/ja
Withdrawn legal-status Critical Current

Links

JP2021566144A 2019-05-09 2020-05-11 がんの処置において使用するための抗dr5抗体の組み合わせの投与レジメン Withdrawn JP2022531894A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845746P 2019-05-09 2019-05-09
US62/845,746 2019-05-09
PCT/EP2020/063101 WO2020225456A1 (en) 2019-05-09 2020-05-11 Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer

Publications (2)

Publication Number Publication Date
JP2022531894A JP2022531894A (ja) 2022-07-12
JP2022531894A5 true JP2022531894A5 (https=) 2023-05-18

Family

ID=70738507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566144A Withdrawn JP2022531894A (ja) 2019-05-09 2020-05-11 がんの処置において使用するための抗dr5抗体の組み合わせの投与レジメン

Country Status (5)

Country Link
US (1) US20220315661A1 (https=)
EP (1) EP3966241A1 (https=)
JP (1) JP2022531894A (https=)
MA (1) MA55881A (https=)
WO (1) WO2020225456A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534726A (ja) * 2020-07-23 2023-08-10 ジェンマブ ビー.ブイ. 多発性骨髄腫の治療に使用するための抗dr5抗体と免疫調節イミド薬との併用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
CN109476737A (zh) 2015-12-01 2019-03-15 根马布有限公司 抗dr5抗体及其使用方法
EP3635005A1 (en) * 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers

Similar Documents

Publication Publication Date Title
JP2023511595A5 (https=)
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2018527383A5 (https=)
CN118267468A (zh) 治疗肿瘤的联用药物组合物
JP2021534188A5 (https=)
CN113613674A (zh) 治疗小细胞肺癌的联用药物组合物
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
WO2023134706A1 (zh) 抗trop-2抗体偶联药物和其他治疗剂的组合用途
JP2025500784A5 (https=)
CN113811298A (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2019517507A (ja) 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
CN120437288A (zh) 治疗卵巢癌的药物组合
CN112121048A (zh) 用于联合治疗食管癌的喹啉类化合物
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
JP2022531894A5 (https=)
KR20240046526A (ko) 소세포폐암 치료용 약학적 조성물
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
TW202545570A (zh) 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用
WO2025103377A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
CN112043832A (zh) 用于联合治疗胃癌的喹啉类化合物
WO2025082449A1 (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
JP2023500480A5 (https=)
CN111065412B (zh) Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途